MX2020005857A - Formulaciones de composiciones de vacuna contra el virus del dengue. - Google Patents
Formulaciones de composiciones de vacuna contra el virus del dengue.Info
- Publication number
- MX2020005857A MX2020005857A MX2020005857A MX2020005857A MX2020005857A MX 2020005857 A MX2020005857 A MX 2020005857A MX 2020005857 A MX2020005857 A MX 2020005857A MX 2020005857 A MX2020005857 A MX 2020005857A MX 2020005857 A MX2020005857 A MX 2020005857A
- Authority
- MX
- Mexico
- Prior art keywords
- dengue virus
- formulations
- virus vaccine
- live attenuated
- vaccine compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención se refiere a formulaciones de vacuna contra el virus del dengue que comprenden al menos un virus del dengue vivo atenuado o flavivirus quimérico vivo atenuado, un amortiguador, un azúcar, un derivado de celulosa, un glicol o alcohol de azúcar, opcionalmente un álcali o sal alcalina y un aminoácido; y formulaciones de vacuna contra el virus del dengue que comprenden al menos un virus del dengue vivo atenuado o flavivirus quimérico vivo atenuado, un amortiguador, un azúcar de al menos 150 mg/ml, un portador, y opcionalmente, un álcali o sal alcalina y un aminoácido.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762595842P | 2017-12-07 | 2017-12-07 | |
PCT/US2018/063541 WO2019112921A1 (en) | 2017-12-07 | 2018-12-03 | Formulations of dengue virus vaccine compositions |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020005857A true MX2020005857A (es) | 2020-09-09 |
Family
ID=66750326
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020005857A MX2020005857A (es) | 2017-12-07 | 2018-12-03 | Formulaciones de composiciones de vacuna contra el virus del dengue. |
Country Status (23)
Country | Link |
---|---|
US (3) | US20200390877A1 (es) |
EP (1) | EP3720487A1 (es) |
JP (1) | JP7042341B2 (es) |
KR (1) | KR102494651B1 (es) |
CN (2) | CN117752780A (es) |
AU (1) | AU2018381213B2 (es) |
BR (1) | BR112020011205A8 (es) |
CA (1) | CA3083772A1 (es) |
CL (1) | CL2020001463A1 (es) |
CO (1) | CO2020006836A2 (es) |
CR (1) | CR20200242A (es) |
DO (1) | DOP2020000098A (es) |
EA (1) | EA202091398A1 (es) |
EC (1) | ECSP20032084A (es) |
GE (1) | GEP20237539B (es) |
IL (1) | IL274897A (es) |
JO (1) | JOP20200140A1 (es) |
MA (1) | MA51060A (es) |
MX (1) | MX2020005857A (es) |
NI (1) | NI202000039A (es) |
PE (1) | PE20210654A1 (es) |
SG (1) | SG11202005251VA (es) |
WO (1) | WO2019112921A1 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7042341B2 (ja) | 2017-12-07 | 2022-03-25 | メルク・シャープ・アンド・ドーム・コーポレーション | デングウイルスワクチン組成物の製剤 |
WO2023069123A1 (en) * | 2021-10-20 | 2023-04-27 | 3M Innovative Properties Company | Phosphate and arginine containing compositions and the delivery of such compositions for virulence suppression |
WO2024073362A2 (en) * | 2022-09-29 | 2024-04-04 | Board Of Regents, The University Of Texas System | Methods and compositions for transport, storage, and delivery of nucleic acids and other molecules |
EP4356925A3 (en) | 2022-10-18 | 2024-05-01 | Takeda Vaccines, Inc. | Dengue vaccine formulation |
Family Cites Families (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69230316T2 (de) | 1991-09-19 | 2000-07-13 | Us Health | Chimäre und/oder wachstumsgehemmte flaviviren |
FR2702660B1 (fr) * | 1993-03-17 | 1995-05-24 | Karl Simpson | Compositions thérapeutiques stabilisées et leur procédé de préparation. |
US6254873B1 (en) | 1995-04-17 | 2001-07-03 | The United States Of America As Represented By The Secretary Of The Army | Inactivated dengue virus vaccine |
US6190859B1 (en) | 1995-04-17 | 2001-02-20 | The United States Of America As Represented By The Secretary Of The Army | Method and kit for detection of dengue virus |
US6432411B1 (en) | 1999-07-13 | 2002-08-13 | Hawaii Biotechnology Group | Recombinant envelope vaccine against flavivirus infection |
US20030180352A1 (en) * | 1999-11-23 | 2003-09-25 | Patel Mahesh V. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
EP2292802B1 (en) | 2001-05-22 | 2015-01-14 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | Development of mutations useful for attenuating dengue viruses and chimeric dengue viruses |
NZ535690A (en) * | 2002-02-26 | 2009-04-30 | Maxygen Inc | Novel flavivirus antigens |
EP1487477A4 (en) * | 2002-03-26 | 2006-07-19 | Immunex Corp | METHOD OF USE OF FLT3 LIGAND IN IMMUNIZATION PROTOCOLS |
SI1554301T1 (sl) | 2002-05-03 | 2011-01-31 | Us Health | VAKCINA ZA DENGO, KI VSEBUJE SKUPNO DELECIJO 30 NUKLEOTIDOV V 3ĹľUTR TIPOV 1 IN 2 DENGE |
US20050123550A1 (en) * | 2003-05-12 | 2005-06-09 | Laurent Philippe E. | Molecules enhancing dermal delivery of influenza vaccines |
US20060177468A1 (en) * | 2005-01-05 | 2006-08-10 | Philadelphia Health and Education Corporation (d/b/a Drexel University College of Medicine | Delivery vehicles, bioactive substances and viral vaccines |
NZ564375A (en) | 2005-06-24 | 2010-02-26 | Intervet Int Bv | Inactivated chimeric flavivirus vaccines and related methods of use |
AU2006299310A1 (en) | 2005-10-04 | 2007-04-12 | Alk-Abello A/S | Solid vaccine formulation |
BRPI0616879A2 (pt) * | 2005-10-04 | 2011-07-05 | Alk Abello As | formulação de vacina sólida |
US8337860B2 (en) | 2006-08-15 | 2012-12-25 | The United States Of America, As Represented By The Secretary Of The Department Of Health & Human Services | Development of dengue virus vaccine components |
US20080275030A1 (en) * | 2007-01-19 | 2008-11-06 | Sveinbjorn Gizurarson | Methods and Compositions for the Delivery of a Therapeutic Agent |
SG10201508397VA (en) * | 2007-04-06 | 2015-11-27 | Takeda Vaccines Inc | Methods and compositions for live attenuated viruses |
EP2143440A1 (fr) * | 2008-07-09 | 2010-01-13 | Sanofi Pasteur | Agent stabilisant et composition vaccinale comprenant un ou plusieurs flavivirus vivants atténués |
US8785173B2 (en) * | 2008-09-24 | 2014-07-22 | Medimmune, Llc | Methods for purification of viruses |
US10369204B2 (en) | 2008-10-02 | 2019-08-06 | Dako Denmark A/S | Molecular vaccines for infectious disease |
EP2405945A4 (en) | 2009-03-13 | 2012-09-12 | Lentigen Corp | NON-INTEGRAL RETROVIRAL VECTOR VACCINES |
GB201002419D0 (en) * | 2010-02-12 | 2010-03-31 | Isis Innovation | Stable live vaccine formulations |
EP2632485A4 (en) | 2010-10-29 | 2014-05-28 | Merck Sharp & Dohme | RECOMBINANT SUBUNIT VACCINE AGAINST DENGUE VIRUS |
PE20140646A1 (es) | 2011-05-26 | 2014-05-29 | Glaxosmithkline Biolog Sa | Vacuna de virus de dengue inactivado |
PL2811981T3 (pl) * | 2012-02-07 | 2019-09-30 | Infectious Disease Research Institute | Ulepszone formulacje adiuwantowe zawierające agonistę TLR4 oraz sposoby ich zastosowania |
US9314519B2 (en) * | 2012-08-21 | 2016-04-19 | Intervet Inc. | Liquid stable virus vaccines |
US9974850B2 (en) * | 2013-01-25 | 2018-05-22 | Board Of Regents, The University Of Texas System | Immunogenic compositions and uses thereof |
US9254332B2 (en) * | 2013-03-15 | 2016-02-09 | Arecor Limited | Stable aqueous formulations of adenovirus vectors |
MY187896A (en) | 2013-06-21 | 2021-10-27 | Merck Sharp & Dohme | Dengue virus vaccine compositions and methods of use thereof |
EP3057612B1 (en) | 2013-10-16 | 2020-05-06 | Merck Sharp & Dohme Corp. | Method of obtaining thermostable dried vaccine formulations |
JP2016534070A (ja) | 2013-10-25 | 2016-11-04 | ロイコケア・アクチェンゲゼルシャフト | 安定化ワクチンの製造のための新規方法 |
WO2015093452A1 (ja) | 2013-12-16 | 2015-06-25 | 武田薬品工業株式会社 | マイクロニードル |
EP3915579A1 (en) * | 2013-12-31 | 2021-12-01 | Infectious Disease Research Institute | Single vial vaccine formulations |
WO2015130157A1 (en) | 2014-02-28 | 2015-09-03 | Universiti Malaya | Enhancement of dengue virus production |
MY192543A (en) | 2014-12-22 | 2022-08-26 | Merck Sharp & Dohme | Dengue virus vaccine compositions and methods of use thereof |
EP3303571A4 (en) * | 2015-06-04 | 2018-10-17 | The University of Hong Kong | Live-attenuated virus and methods of production and use |
WO2016203025A1 (en) * | 2015-06-17 | 2016-12-22 | Curevac Ag | Vaccine composition |
US10004795B2 (en) | 2015-09-08 | 2018-06-26 | Fundacao Butantan | Process for preparing an attenuated tetravalent dengue vaccine |
KR20180041761A (ko) * | 2015-09-30 | 2018-04-24 | 파나세아 바이오테크 리미티드 | 안정한 약독화된 재조합 뎅기 생백신 |
WO2017109698A1 (en) | 2015-12-22 | 2017-06-29 | Glaxosmithkline Biologicals Sa | Immunogenic formulation |
TWI763660B (zh) | 2016-03-25 | 2022-05-11 | 美商威特拉公司 | 登革病毒的抗體分子之配方設計 |
WO2017179017A1 (en) * | 2016-04-13 | 2017-10-19 | Takeda Vaccines, Inc. | Compositions and methods of vaccination against dengue virus in children and young adults |
TW202309276A (zh) | 2016-08-03 | 2023-03-01 | 美商武田疫苗股份有限公司 | 用於與經改良之調配物一起穩定黃病毒的組成物及方法 |
AU2017327009A1 (en) | 2016-09-19 | 2019-04-04 | Vaxess Technologies, Inc. | Vaccine formulations with increased stability |
US20200392468A1 (en) | 2017-03-30 | 2020-12-17 | Merck Sharp & Dohme Corp. | Addition of nucleases directly to cell culture to facilitate digestion and clearance of host cell nucleic acids |
EA202090967A1 (ru) | 2017-10-16 | 2020-08-12 | Серум Инститьют Оф Индия Прайват Лимитед | Стабильные составы вакцин, включающих, в частности, живой аттенуированный рекомбинантный флавивирус, и процесс их приготовления |
JP7042341B2 (ja) | 2017-12-07 | 2022-03-25 | メルク・シャープ・アンド・ドーム・コーポレーション | デングウイルスワクチン組成物の製剤 |
-
2018
- 2018-12-03 JP JP2020530648A patent/JP7042341B2/ja active Active
- 2018-12-03 PE PE2020000684A patent/PE20210654A1/es unknown
- 2018-12-03 WO PCT/US2018/063541 patent/WO2019112921A1/en unknown
- 2018-12-03 EA EA202091398A patent/EA202091398A1/ru unknown
- 2018-12-03 AU AU2018381213A patent/AU2018381213B2/en active Active
- 2018-12-03 MX MX2020005857A patent/MX2020005857A/es unknown
- 2018-12-03 JO JOP/2020/0140A patent/JOP20200140A1/ar unknown
- 2018-12-03 BR BR112020011205A patent/BR112020011205A8/pt unknown
- 2018-12-03 EP EP18887100.8A patent/EP3720487A1/en active Pending
- 2018-12-03 GE GEAP201815384A patent/GEP20237539B/en unknown
- 2018-12-03 KR KR1020207019204A patent/KR102494651B1/ko active IP Right Grant
- 2018-12-03 SG SG11202005251VA patent/SG11202005251VA/en unknown
- 2018-12-03 MA MA051060A patent/MA51060A/fr unknown
- 2018-12-03 CA CA3083772A patent/CA3083772A1/en active Pending
- 2018-12-03 CN CN202311806711.3A patent/CN117752780A/zh active Pending
- 2018-12-03 CR CR20200242A patent/CR20200242A/es unknown
- 2018-12-03 US US16/769,837 patent/US20200390877A1/en not_active Abandoned
- 2018-12-03 CN CN201880079043.XA patent/CN111447947B/zh active Active
-
2020
- 2020-05-25 IL IL274897A patent/IL274897A/en unknown
- 2020-05-29 DO DO2020000098A patent/DOP2020000098A/es unknown
- 2020-06-01 NI NI202000039A patent/NI202000039A/es unknown
- 2020-06-01 CL CL2020001463A patent/CL2020001463A1/es unknown
- 2020-06-02 CO CONC2020/0006836A patent/CO2020006836A2/es unknown
- 2020-06-12 EC ECSENADI202032084A patent/ECSP20032084A/es unknown
-
2022
- 2022-07-26 US US17/815,037 patent/US11883480B2/en active Active
-
2023
- 2023-12-06 US US18/530,421 patent/US20240131144A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20200390877A1 (en) | 2020-12-17 |
ECSP20032084A (es) | 2020-08-31 |
CA3083772A1 (en) | 2019-06-13 |
AU2018381213B2 (en) | 2022-03-17 |
EA202091398A1 (ru) | 2020-09-01 |
CN111447947B (zh) | 2024-01-12 |
US20230061673A1 (en) | 2023-03-02 |
KR20200096272A (ko) | 2020-08-11 |
US20240131144A1 (en) | 2024-04-25 |
JP7042341B2 (ja) | 2022-03-25 |
JOP20200140A1 (ar) | 2022-10-30 |
CL2020001463A1 (es) | 2020-09-25 |
CO2020006836A2 (es) | 2020-06-19 |
CR20200242A (es) | 2020-07-17 |
MA51060A (fr) | 2021-03-17 |
NI202000039A (es) | 2020-09-24 |
JP2021505588A (ja) | 2021-02-18 |
DOP2020000098A (es) | 2020-08-31 |
GEP20237539B (en) | 2023-09-11 |
US11883480B2 (en) | 2024-01-30 |
CN111447947A (zh) | 2020-07-24 |
CN117752780A (zh) | 2024-03-26 |
AU2018381213A1 (en) | 2020-06-11 |
EP3720487A1 (en) | 2020-10-14 |
KR102494651B1 (ko) | 2023-01-31 |
BR112020011205A2 (pt) | 2020-11-17 |
BR112020011205A8 (pt) | 2023-02-07 |
IL274897A (en) | 2020-07-30 |
WO2019112921A1 (en) | 2019-06-13 |
PE20210654A1 (es) | 2021-03-31 |
SG11202005251VA (en) | 2020-07-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JOP20200140A1 (ar) | صيغ لتركيبات لقاح فيروس حُمى الضنك | |
GEP20227374B (en) | Novel, highly active pyrazolo-piperidine substituted indole-2-carboxamides active against the hepatitis b virus (hbv) | |
PH12020550478A1 (en) | Creamer composition | |
PH12020550051A1 (en) | Glp-1 compositions and uses thereof | |
WO2015044337A3 (en) | Dry formulations of vaccines that are room temperature stable | |
NZ704584A (en) | Liquid stable virus vaccines | |
PH12019550249A1 (en) | Solid compositions for oral administration | |
MX2012003987A (es) | Composiciones desinfectantes. | |
MX2015006998A (es) | Una composicion acuosa estable que comprende insulina humana o un analogo o derivado de la misma. | |
MX2015012737A (es) | Vacunas de virus bovino liquidas estables. | |
EA201991041A1 (ru) | Вакцина против свиного парвовируса и вируса свиного репродуктивного и респираторного синдрома и способы ее получения | |
WO2017214596A8 (en) | Compositions and methods for preventing and treating zika virus infection | |
MX2020009935A (es) | Formulaciones acuosas y estables de anticuerpos anti-tau. | |
WO2016038521A8 (en) | Pharmaceutical compositions of liraglutide | |
EA201690859A1 (ru) | Предотвращение инфекций, вызываемых staphylococcus aureus, гликопротеиновыми вакцинами, синтезированными в escherichia coli | |
ZA201908610B (en) | Il-15 protein complex pharmaceutical composition and uses thereof | |
WO2018091729A3 (en) | Aqueous pharmaceutical formulations | |
MX2021004331A (es) | Composiciones estables de semaglutida y usos de las mismas. | |
GB2539148A (en) | Vaccine compositions | |
EA201991023A1 (ru) | Фармацевтическая композиция для парентерального введения, содержащая карглумовую кислоту | |
TW201613557A (en) | Stable aqueous recombinant protein formulations | |
MX2015010930A (es) | Formulaciones para el tratamiento de semillas. | |
GEP20237486B (en) | Formulations of copanlisib | |
PH12019501946A1 (en) | Liquid composition containing pradofloxacin | |
CL2022002207A1 (es) | Formulaciones de composiciones de vacuna contra el virus del dengue (divisional de solicitud 202001463). |